论文信息 - The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. - 字舞流文

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

D. Schadendorf | K. Flaherty | P. Ascierto | R. Dummer | A. Ribas | H. Tawbi | M. Mandalà | P. Nathan | G. Long | C. Robert | C. Lebbé | E. Richtig | N. Yamazaki | V. Atkinson | E. Gasal | A. Arance | Neha Pakhle | Aisha Masood